Microbix Biosystems Inc. (MBX.TO)
CAD 0.36
(-5.26%)
CAD 0.36
(-5.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 7.48 Million CAD | -32.75% |
| 2022 | 11.12 Million CAD | 0.73% |
| 2021 | 11.04 Million CAD | 136.95% |
| 2020 | 4.66 Million CAD | -28.81% |
| 2019 | 6.54 Million CAD | 21.94% |
| 2018 | 5.36 Million CAD | 11.58% |
| 2017 | 4.81 Million CAD | -3.37% |
| 2016 | 4.98 Million CAD | -14.72% |
| 2015 | 5.83 Million CAD | 29.44% |
| 2014 | 4.51 Million CAD | 17.67% |
| 2013 | 3.83 Million CAD | 39.18% |
| 2012 | 2.75 Million CAD | -7.7% |
| 2011 | 2.98 Million CAD | -20.08% |
| 2010 | 3.73 Million CAD | 4.77% |
| 2009 | 3.56 Million CAD | 41.75% |
| 2008 | 2.51 Million CAD | 30.1% |
| 2007 | 1.93 Million CAD | 2.12% |
| 2006 | 1.89 Million CAD | -29.93% |
| 2005 | 2.7 Million CAD | 4.83% |
| 2004 | 2.57 Million CAD | 41.37% |
| 2003 | 1.82 Million CAD | -7.53% |
| 2002 | 1.97 Million CAD | -3.31% |
| 2001 | 2.03 Million CAD | 59.38% |
| 2000 | 1.27 Million CAD | 27.92% |
| 1999 | 1 Million CAD | -60.0% |
| 1998 | 2.5 Million CAD | 13.64% |
| 1997 | 2.2 Million CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 6.22 Million CAD | 336.6% |
| 2024 Q2 | 2.97 Million CAD | -52.25% |
| 2024 Q3 | 2.74 Million CAD | -7.5% |
| 2023 Q3 | 2.34 Million CAD | -7.3% |
| 2023 Q2 | 2.52 Million CAD | 113.1% |
| 2023 Q1 | 1.18 Million CAD | -41.3% |
| 2023 FY | 7.48 Million CAD | -32.75% |
| 2023 Q4 | 1.42 Million CAD | -39.17% |
| 2022 Q2 | 3.11 Million CAD | -3.28% |
| 2022 Q1 | 3.22 Million CAD | -0.74% |
| 2022 FY | 11.12 Million CAD | 0.73% |
| 2022 Q4 | 2.02 Million CAD | -26.95% |
| 2022 Q3 | 2.76 Million CAD | -11.24% |
| 2021 Q2 | 2.6 Million CAD | 49.09% |
| 2021 FY | 11.04 Million CAD | 136.95% |
| 2021 Q3 | 3.44 Million CAD | 32.27% |
| 2021 Q4 | 3.24 Million CAD | -5.81% |
| 2021 Q1 | 1.74 Million CAD | 85.69% |
| 2020 Q3 | 1.35 Million CAD | 2.65% |
| 2020 Q4 | 940.95 Thousand CAD | -30.59% |
| 2020 FY | 4.66 Million CAD | -28.81% |
| 2020 Q1 | 1.04 Million CAD | -33.78% |
| 2020 Q2 | 1.32 Million CAD | 26.53% |
| 2019 Q1 | 1.29 Million CAD | -6.1% |
| 2019 Q2 | 2.16 Million CAD | 67.49% |
| 2019 FY | 6.54 Million CAD | 21.94% |
| 2019 Q4 | 1.57 Million CAD | 3.74% |
| 2019 Q3 | 1.51 Million CAD | -29.71% |
| 2018 Q3 | 1.52 Million CAD | 32.19% |
| 2018 Q2 | 1.15 Million CAD | -12.62% |
| 2018 Q1 | 1.31 Million CAD | 21.56% |
| 2018 Q4 | 1.37 Million CAD | -9.79% |
| 2018 FY | 5.36 Million CAD | 11.58% |
| 2017 FY | 4.81 Million CAD | -3.37% |
| 2017 Q1 | 814.52 Thousand CAD | -61.81% |
| 2017 Q4 | 1.08 Million CAD | -27.56% |
| 2017 Q3 | 1.49 Million CAD | 5.85% |
| 2017 Q2 | 1.41 Million CAD | 73.72% |
| 2016 Q4 | 2.13 Million CAD | 84.34% |
| 2016 FY | 4.98 Million CAD | -14.72% |
| 2016 Q1 | 357.45 Thousand CAD | -83.18% |
| 2016 Q2 | 1.33 Million CAD | 272.96% |
| 2016 Q3 | 1.15 Million CAD | -13.23% |
| 2015 Q2 | 1.33 Million CAD | 17.96% |
| 2015 Q1 | 1.12 Million CAD | -2.9% |
| 2015 Q4 | 2.12 Million CAD | 69.17% |
| 2015 Q3 | 1.25 Million CAD | -5.63% |
| 2015 FY | 5.83 Million CAD | 29.44% |
| 2014 Q3 | 1.15 Million CAD | 5.0% |
| 2014 FY | 4.51 Million CAD | 17.67% |
| 2014 Q4 | 1.16 Million CAD | 0.98% |
| 2014 Q2 | 1.09 Million CAD | -0.67% |
| 2014 Q1 | 1.1 Million CAD | -21.34% |
| 2013 Q4 | 1.4 Million CAD | 51.68% |
| 2013 Q2 | 1.01 Million CAD | 148.74% |
| 2013 Q1 | 409.61 Thousand CAD | -13.24% |
| 2013 Q3 | 924.56 Thousand CAD | -9.26% |
| 2013 FY | 3.83 Million CAD | 39.18% |
| 2012 FY | 2.75 Million CAD | -7.7% |
| 2012 Q3 | 1.97 Million CAD | 105.03% |
| 2012 Q2 | 963.67 Thousand CAD | 50.15% |
| 2012 Q1 | 641.78 Thousand CAD | -18.64% |
| 2012 Q4 | 472.11 Thousand CAD | -76.11% |
| 2011 Q4 | 788.86 Thousand CAD | 8.39% |
| 2011 Q2 | 1.03 Million CAD | 139.87% |
| 2011 Q1 | 431.93 Thousand CAD | -66.72% |
| 2011 Q3 | 727.83 Thousand CAD | -29.75% |
| 2011 FY | 2.98 Million CAD | -20.08% |
| 2010 Q2 | 1.1 Million CAD | 56.12% |
| 2010 Q4 | 1.29 Million CAD | 107.49% |
| 2010 FY | 3.73 Million CAD | 4.77% |
| 2010 Q1 | 707.13 Thousand CAD | -24.75% |
| 2010 Q3 | 625.58 Thousand CAD | -43.33% |
| 2009 Q3 | 738.47 Thousand CAD | -20.6% |
| 2009 Q2 | 930.12 Thousand CAD | -2.74% |
| 2009 Q1 | 956.3 Thousand CAD | 53.53% |
| 2009 FY | 3.56 Million CAD | 41.75% |
| 2009 Q4 | 939.67 Thousand CAD | 27.24% |
| 2008 Q3 | 829.18 Thousand CAD | 48.09% |
| 2008 Q4 | 622.86 Thousand CAD | -24.88% |
| 2008 Q2 | 559.92 Thousand CAD | 11.37% |
| 2008 Q1 | 502.76 Thousand CAD | 41.6% |
| 2008 FY | 2.51 Million CAD | 30.1% |
| 2007 Q4 | 355.04 Thousand CAD | -38.98% |
| 2007 Q3 | 581.83 Thousand CAD | -10.13% |
| 2007 Q2 | 647.41 Thousand CAD | 85.68% |
| 2007 Q1 | 348.67 Thousand CAD | 55.23% |
| 2007 FY | 1.93 Million CAD | 2.12% |
| 2006 Q4 | 224.62 Thousand CAD | -55.21% |
| 2006 Q3 | 501.51 Thousand CAD | -1.4% |
| 2006 Q2 | 508.65 Thousand CAD | -22.7% |
| 2006 FY | 1.89 Million CAD | -29.93% |
| 2006 Q1 | 658.03 Thousand CAD | 29.28% |
| 2005 Q2 | 614.87 Thousand CAD | -20.78% |
| 2005 FY | 2.7 Million CAD | 4.83% |
| 2005 Q1 | 776.13 Thousand CAD | -36.84% |
| 2005 Q4 | 508.99 Thousand CAD | -36.49% |
| 2005 Q3 | 801.42 Thousand CAD | 30.34% |
| 2004 FY | 2.57 Million CAD | 41.37% |
| 2004 Q2 | 468.66 Thousand CAD | 1.31% |
| 2004 Q3 | 416.73 Thousand CAD | -11.08% |
| 2004 Q4 | 1.22 Million CAD | 194.89% |
| 2004 Q1 | 462.61 Thousand CAD | -27.21% |
| 2003 Q3 | 330.41 Thousand CAD | -28.89% |
| 2003 Q2 | 464.69 Thousand CAD | 18.5% |
| 2003 Q1 | 392.15 Thousand CAD | -22.38% |
| 2003 FY | 1.82 Million CAD | -7.53% |
| 2003 Q4 | 635.52 Thousand CAD | 92.34% |
| 2002 Q2 | 536.74 Thousand CAD | 93.79% |
| 2002 Q4 | 505.19 Thousand CAD | -22.57% |
| 2002 Q3 | 652.41 Thousand CAD | 21.55% |
| 2002 FY | 1.97 Million CAD | -3.31% |
| 2002 Q1 | 276.97 Thousand CAD | -33.67% |
| 2001 Q4 | 417.58 Thousand CAD | -17.21% |
| 2001 Q3 | 504.39 Thousand CAD | -6.73% |
| 2001 Q2 | 540.78 Thousand CAD | -6.75% |
| 2001 Q1 | 579.93 Thousand CAD | 52.92% |
| 2001 FY | 2.03 Million CAD | 59.38% |
| 2000 FY | 1.27 Million CAD | 27.92% |
| 2000 Q4 | 379.24 Thousand CAD | 26.42% |
| 2000 Q3 | 300 Thousand CAD | 0.0% |
| 2000 Q2 | 300 Thousand CAD | 0.0% |
| 2000 Q1 | 300 Thousand CAD | 0.0% |
| 1999 Q2 | 100 Thousand CAD | -66.67% |
| 1999 Q3 | 400 Thousand CAD | 300.0% |
| 1999 Q1 | 300 Thousand CAD | 200.0% |
| 1999 Q4 | 300 Thousand CAD | -25.0% |
| 1999 FY | 1 Million CAD | -60.0% |
| 1998 Q4 | 100 Thousand CAD | -92.31% |
| 1998 Q3 | 1.3 Million CAD | 62.5% |
| 1998 Q2 | 800 Thousand CAD | 166.67% |
| 1998 FY | 2.5 Million CAD | 13.64% |
| 1998 Q1 | 300 Thousand CAD | -25.0% |
| 1997 Q1 | 500 Thousand CAD | 0.0% |
| 1997 Q4 | 400 Thousand CAD | -50.0% |
| 1997 Q3 | 800 Thousand CAD | 60.0% |
| 1997 Q2 | 500 Thousand CAD | 0.0% |
| 1997 FY | 2.2 Million CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Appili Therapeutics Inc. | 813.74 Thousand CAD | -819.371% |
| Eupraxia Pharmaceuticals Inc. | -209.91 Thousand CAD | 3664.05% |
| Helix BioPharma Corp. | -14 Thousand CAD | 53538.1% |
| Medicenna Therapeutics Corp. | -5000.00 CAD | 149726.68% |
| Satellos Bioscience Inc. | -8.81 Million CAD | 184.851% |
| Oncolytics Biotech Inc. | -403 Thousand CAD | 1956.41% |
| Sernova Corp. | -445.55 Thousand CAD | 1779.12% |